DK1276752T3 - Fremgangsmåde til vurdering af risikoen for, at en person udvikler vaskulære komplikationer - Google Patents

Fremgangsmåde til vurdering af risikoen for, at en person udvikler vaskulære komplikationer

Info

Publication number
DK1276752T3
DK1276752T3 DK01925836.7T DK01925836T DK1276752T3 DK 1276752 T3 DK1276752 T3 DK 1276752T3 DK 01925836 T DK01925836 T DK 01925836T DK 1276752 T3 DK1276752 T3 DK 1276752T3
Authority
DK
Denmark
Prior art keywords
risk
vascular complications
assessing
procedure
developing vascular
Prior art date
Application number
DK01925836.7T
Other languages
English (en)
Inventor
Andrew P Levy
Original Assignee
Rappaport Family Inst For Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/556,469 external-priority patent/US6251608B1/en
Application filed by Rappaport Family Inst For Res filed Critical Rappaport Family Inst For Res
Application granted granted Critical
Publication of DK1276752T3 publication Critical patent/DK1276752T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6862—Ligase chain reaction [LCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Financial Or Insurance-Related Operations Such As Payment And Settlement (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Eye Examination Apparatus (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
DK01925836.7T 2000-04-20 2001-04-19 Fremgangsmåde til vurdering af risikoen for, at en person udvikler vaskulære komplikationer DK1276752T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/556,469 US6251608B1 (en) 2000-04-20 2000-04-20 Method of determining a potential of a hyperglycemic patients of developing vascular complications
US23769600P 2000-10-05 2000-10-05
US09/688,121 US6599702B1 (en) 2000-04-20 2000-10-16 Method of evaluating a risk of a subject of developing vascular complications
PCT/IL2001/000368 WO2001080711A2 (en) 2000-04-20 2001-04-19 Method of evaluating a risk of a subject of developing vascular complications

Publications (1)

Publication Number Publication Date
DK1276752T3 true DK1276752T3 (da) 2011-02-07

Family

ID=27399009

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01925836.7T DK1276752T3 (da) 2000-04-20 2001-04-19 Fremgangsmåde til vurdering af risikoen for, at en person udvikler vaskulære komplikationer

Country Status (6)

Country Link
US (1) US6599702B1 (da)
EP (1) EP1276752B1 (da)
AT (1) ATE486085T1 (da)
AU (1) AU5251101A (da)
DK (1) DK1276752T3 (da)
WO (1) WO2001080711A2 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608393B2 (en) * 2000-04-20 2009-10-27 Rappaport Family Institute For Research In The Medical Sciences Methods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients
JP2006512079A (ja) * 2003-01-02 2006-04-13 ラッパポート・ファミリー・インスティチュート・フォー・リサーチ・イン・ザ・メディカル・サイエンシズ 高血糖性患者の心疾患を予防するための抗酸化治療の有効性を予測する方法
US7610257B1 (en) * 2006-01-10 2009-10-27 Sas Institute Inc. Computer-implemented risk evaluation systems and methods
US8280805B1 (en) 2006-01-10 2012-10-02 Sas Institute Inc. Computer-implemented risk evaluation systems and methods
US7912773B1 (en) * 2006-03-24 2011-03-22 Sas Institute Inc. Computer-implemented data storage systems and methods for use with predictive model systems
WO2008143883A1 (en) * 2007-05-14 2008-11-27 Synvista Therapeutics, Inc. Use of haptoglobin genotyping in diagnosis and treatment of defective reverse cholesterol transport (rct)
US20090018110A1 (en) * 2007-06-06 2009-01-15 Andrew Levy Haptoglobin genotyping for prognosis and treatment of chronic vasospasm following subarachnoid hemorrhage (SAH)
US8515862B2 (en) * 2008-05-29 2013-08-20 Sas Institute Inc. Computer-implemented systems and methods for integrated model validation for compliance and credit risk
CA2727790A1 (en) 2008-06-13 2009-12-17 Synvista Therapeutics, Inc. Reagents and methods for detecting a polymorphic protein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1010935A7 (nl) * 1997-02-19 1999-03-02 Delanghe Joris Richard Siegfri Fenotypering van humaan haptoglobine in serum of plasma door middel van quantitatieve agglutinatie met streptococcus antigenen.
US6251608B1 (en) * 2000-04-20 2001-06-26 Technion Research & Development Foundation, Ltd. Method of determining a potential of a hyperglycemic patients of developing vascular complications

Also Published As

Publication number Publication date
US6599702B1 (en) 2003-07-29
WO2001080711A2 (en) 2001-11-01
WO2001080711A3 (en) 2002-03-28
EP1276752A4 (en) 2007-04-25
EP1276752A2 (en) 2003-01-22
AU5251101A (en) 2001-11-07
ATE486085T1 (de) 2010-11-15
EP1276752B1 (en) 2010-10-27

Similar Documents

Publication Publication Date Title
AU3084802A (en) Inflammatory markers as tools in the detection and prevention of diabetes mellitus and as tools to aid in the selection of agents to be used for the prevention and treatment of diabetes
DK1694203T3 (da) System eller fremgangsmåde til vurdering af en person perifere blodcirkulation
DK1003501T3 (da) Anvendelse af et middel til reduktion af risikoen for kardiovaskulær sygdom
HUP0301877A2 (hu) Aromatáz inhibitorok és monoklonális anti-HER2 ellenanyagok mint tumorellenes szerek
EP1664202A4 (en) Fluorinated dyes or dyes and their uses
DE60138829D1 (de) Verfahren zur unterscheidung des reizkolons von der entzündlichen darmerkrankung (inflammatory bowel disease, ibd) und zur überwachung von patienten mit ibd unter verwendung von endogenem gesamt-lactoferrin als marker
DK1276752T3 (da) Fremgangsmåde til vurdering af risikoen for, at en person udvikler vaskulære komplikationer
DK0749582T3 (da) Fremgangsmåde til diagnosticering af præeklampsi
DK2298362T3 (da) Reagerende paramagnetiske kontrastmidler til magnetresonansbilledteknik
DK1335666T3 (da) Sensor og fremgangsmåde til måling af fysiologiske parametre
TW200719866A (en) Method of measuring blood circulation velocity by controlling breath
ATE426675T1 (de) Differenzialdiagnostik mit hepcidin
DK1800134T3 (da) Fremgangsmåde til diagnosticering og behandling af Chron's sygdom
WO2001080712A3 (en) Method of determining a risk of hyperglycemic patients of developing a cardiovascular disease
ATE546548T1 (de) Verfahren zur prognose des nutzens einer antioxidationshemmenden therapie zur vorbeugung von herz-kreislauf-erkrankungen bei hyperglykämischen patienten
WO2006113880A3 (en) Intact igfbp-3 as a colon cancer risk factor in patients with inflammatory bowel disease
ATE383564T1 (de) Optisches interferometer
DK1558929T3 (da) Kvantificering af stresseksponering
EA200100868A1 (ru) Предрасположенность к инфекции, связанная с интенсивными физическими упражнениями или другим стрессом
EP1812063A4 (en) MONOCLONAL ANTIBODIES AGAINST THE CANDIDA ALBICANS PROPEPTIDE AND METHOD OF USE
IL113346A0 (en) Method to identify immunocompromised patients at high risk for cryptococcosis
RU2002111522A (ru) Способ оценки восстановления слуховой функции в остром периоде сенсоневральной тугоухости
DE69928950D1 (de) Methode zur optimierung der verwendung von 6-mercaptopurin in der behandlung von immun-vermittelten gastrointestinalen störungen
RU2004121380A (ru) Способ оценки функции щитовидной железы
UA34205A (uk) Спосіб визначення захисної функції плаценти